Effects of concomitant proton pump inhibitor use on immune checkpoint inhibitor efficacy among patients with advanced cancer

References

• Billan S, Kaidar-Person O, Gil Z. Kaidar-Person O and Gil Z. Treatment after progression in the era of immunotherapy. Lancet Oncol. 2020;21(10):e463–9. doi:10.1016/S1470-2045(20)30328-4.
   PubMed Web of Science ®Google Scholar
• Postow MA, Callahan MK, Wolchok JD. Callahan MK and Wolchok JD. Immune Checkpoint Blockade in Cancer Therapy. J Clin Oncol. 2015;33(17):1974–1982. doi:10.1200/JCO.2014.59.4358.
   PubMed Web of Science ®Google Scholar
• Mok TSK, Wu YL, Kudaba I, Kowalski DM, Cho BC, Turna HZ, Castro G Jr., Srimuninnimit V, Laktionov KK, Bondarenko I, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019;393:1819–1830. doi:10.1016/S0140-6736(18)32409-7.
   PubMed Web of Science ®Google Scholar
• Nosaki K, Saka H, Hosomi Y, Baas P, De Castro G Jr., Reck M, Wu YL, Brahmer JR, Felip E, Sawada T, et al. Kush DA and Lopes G. Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies. Lung Cancer. 2019;135:188–195. doi:10.1016/j.lungcan.2019.07.004.
   PubMed Web of Science ®Google Scholar
• Gadgeel S, Rodriguez-Abreu D, Speranza G, Esteban E, Felip E, Domine M, Hui R, Hochmair MJ, Clingan P, Powell SF, et al. Pietanza MC and Garassino MC. Updated Analysis From KEYNOTE-189: pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer. J Clin Oncol. 2020;38(14):1505–1517. doi:10.1200/JCO.19.03136.
   PubMed Web of Science ®Google Scholar
• Gettinger S, Horn L, Jackman D, Spigel D, Antonia S, Hellmann M, Powderly J, Heist R, Sequist LV, Smith DC, et al. Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: results From the CA209-003 Study. J Clin Oncol. 2018;36(17):1675–1684. doi:10.1200/JCO.2017.77.0412.
   PubMed Web of Science ®Google Scholar
• Paz-Ares L, Vicente D, Tafreshi A, Robinson A, Soto Parra H, Mazieres J, Hermes B, Cicin I, Medgyasszay B, Rodriguez-Cid J, et al. Placebo-controlled trial of pembrolizumab plus chemotherapy in patients with metastatic squamous NSCLC: protocol-specified final analysis of KEYNOTE-407. J Thorac Oncol. 2020;15(10):1657–1669. doi:10.1016/j.jtho.2020.06.015.
   PubMed Web of Science ®Google Scholar
• Keilholz U, Pa A, Dummer R, Robert C, Lorigan P, Van Akkooi A, Arance A, Cu B, Chiarion SV, Donia M, et al. Testori A and Michielin O. ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee. Ann Oncol. 2020;31(11):1435–1448. doi:10.1016/j.annonc.2020.07.004.
   PubMed Web of Science ®Google Scholar
• Marabelle A, Fakih M, Lopez J, Shah M, Shapira-Frommer R, Nakagawa K, Chung HC, Kindler HL, Lopez-Martin JA, Miller WH Jr., et al. Norwood K and Bang YJ. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 2020;21(10):1353–1365. doi:10.1016/S1470-2045(20)30445-9.
   PubMed Web of Science ®Google Scholar
• Marabelle A, Le DT, Ascierto PA, Di Giacomo AM, De Jesus-Acosta A, Delord JP, Geva R, Gottfried M, Penel N, Hansen AR, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase ii KEYNOTE-158 Study. J Clin Oncol. 2020;38:1–10.
   PubMed Web of Science ®Google Scholar
• Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fulop A, Gottfried M, Peled N, Tafreshi A, Cuffe S, et al. Pietanza MC and Brahmer JR. Updated Analysis of KEYNOTE-024: pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater. J Clin Oncol. 2019;37(7):537–546. doi:10.1200/JCO.18.00149.
   PubMed Web of Science ®Google Scholar
• Geva-Zatorsky N, Sefik E, Kua L, Pasman L, Tan TG, Ortiz-Lopez A, Yanortsang TB, Yang L, Jupp R, Mathis D. Benoist C and Kasper DL. Mining the human gut microbiota for immunomodulatory organisms. Cell. 2017;168(5):928–943 e911. doi:10.1016/j.cell.2017.01.022.
   PubMed Web of Science ®Google Scholar
• Schluter J, Peled JU, Taylor BP, Markey KA, Smith M, Taur Y, Niehus R, Staffas A, Dai A, Fontana E, et al. The gut microbiota is associated with immune cell dynamics in humans. Nature. 2020;588(7837):303–307. doi:10.1038/s41586-020-2971-8.
   PubMed Web of Science ®Google Scholar
• Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, Prieto PA, Vicente D, Hoffman K, Wei SC, et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science. 2018;359(6371):97–103. doi:10.1126/science.aan4236.
   PubMed Web of Science ®Google Scholar
• Tanoue T, Morita S, Plichta DR, Skelly AN, Suda W, Sugiura Y, Narushima S, Vlamakis H, Motoo I, Sugita K, et al. A defined commensal consortium elicits CD8 T cells and anti-cancer immunity. Nature. 2019;565:600–605. doi:10.1038/s41586-019-0878-z.
   PubMed Web of Science ®Google Scholar
• Rogers MAM, Aronoff DM. The influence of non-steroidal anti-inflammatory drugs on the gut microbiome. Clin Microbiol Infect. 2016;22(2):178 e171–178 e179. doi:10.1016/j.cmi.2015.10.003.
   Web of Science ®Google Scholar
• Buti S, Bersanelli M, Perrone F, Tiseo M, Tucci M, Adamo V, Stucci LS, Russo A, Tanda ET, Spagnolo F, et al. Ascierto PA and Cortellini A. Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index. Eur J Cancer. 2020;142:18–28. doi:10.1016/j.ejca.2020.09.033.
   PubMed Web of Science ®Google Scholar
• Chalabi M, Cardona A, Nagarkar DR, Dhawahir Scala A, Gandara DR, Rittmeyer A, Albert ML, Powles T, Kok M, Fg H, et al. Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials. Ann Oncol. 2020;31(4):525–531. doi:10.1016/j.annonc.2020.01.006.
   PubMed Web of Science ®Google Scholar
• Cortellini A, Tucci M, Adamo V, Stucci LS, Russo A, Tanda ET, Spagnolo F, Rastelli F, Bisonni R, Santini D, et al. Ficorella C and Ascierto PA. Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice. J Immunother Cancer. 2020;8:e001361.
   PubMed Web of Science ®Google Scholar
• Hakozaki T, Okuma Y, Omori M, Hosomi Y. Omori M and Hosomi Y. Impact of prior antibiotic use on the efficacy of nivolumab for non-small cell lung cancer. Oncol Lett. 2019;17(3):2946–2952. doi:10.3892/ol.2019.9899.
   PubMed Web of Science ®Google Scholar
• Hopkins AM, Kichenadasse G, Karapetis CS, Rowland A, Sorich MJ. Rowland A and Sorich MJ. concomitant proton pump inhibitor use and survival in urothelial carcinoma treated with atezolizumab. Clin Cancer Res. 2020;26(20):5487–5493. doi:10.1158/1078-0432.CCR-20-1876.
   PubMed Web of Science ®Google Scholar
• Iglesias-Santamaria A. Impact of antibiotic use and other concomitant medications on the efficacy of immune checkpoint inhibitors in patients with advanced cancer. Clin Transl Oncol. 2020;22(9):1481–1490. doi:10.1007/s12094-019-02282-w.
   PubMed Web of Science ®Google Scholar
• Mukherjee S, Ibrahimi S, Khalid B, Roman D, Zhao D, Aljumaily R. Zhao D and Aljumaily R. Do proton pump inhibitors modulate the efficacy of anti-PD-1/PD-L1 therapy? A retrospective study. J Oncol Pharm Pract. 2019;25(3):762–764. doi:10.1177/1078155218771152.
   PubMed Web of Science ®Google Scholar
• Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillere R, Fluckiger A, Messaoudene M, Rauber C, Roberti MP, et al. Kroemer G and Zitvogel L. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 2018;359(6371):91–97. doi:10.1126/science.aan3706.
   PubMed Web of Science ®Google Scholar
• Zhao S, Gao G, Li W, Li X, Zhao C, Jiang T, Jia Y, He Y, Li A, Su C, et al. Chen X and Zhou C. Antibiotics are associated with attenuated efficacy of anti-PD-1/PD-L1 therapies in Chinese patients with advanced non-small cell lung cancer. Lung Cancer. 2019;130:10–17. doi:10.1016/j.lungcan.2019.01.017.
   PubMed Web of Science ®Google Scholar
• Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015;349(jan02 1):g7647. doi:10.1136/bmj.g7647.
   PubMed Web of Science ®Google Scholar
• Altman DG, Bland JM, Bland JM. Interaction revisited: the difference between two estimates. BMJ. 2003;326(7382):219. doi:10.1136/bmj.326.7382.219.
   PubMed Web of Science ®Google Scholar
• Conforti F, Pala L, Bagnardi V, Viale G, De Pas T, Pagan E, Pennacchioli E, Cocorocchio E, Ferrucci PF, De Marinis F, et al. Sex-based heterogeneity in response to lung cancer immunotherapy: a systematic review and meta-analysis. J Natl Cancer Inst. 2019;111(8):772–781. doi:10.1093/jnci/djz094.
   PubMedGoogle Scholar
• Qin BD, Jiao XD, Liu J, Liu K, He X, Wu Y, Ling Y, Duan XP, Qin WX, Wang Z, et al. The effect of liver metastasis on efficacy of immunotherapy plus chemotherapy in advanced lung cancer. Crit Rev Oncol Hematol. 2020;147:102893. doi:10.1016/j.critrevonc.2020.102893.
   PubMed Web of Science ®Google Scholar
• Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–1558. doi:10.1002/sim.1186.
   PubMed Web of Science ®Google Scholar
• Higgins JP, Thompson SG, Jj D, Dg A. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–560. doi:10.1136/bmj.327.7414.557.
   PubMed Web of Science ®Google Scholar
• Li C, Xia Z, Li A, Meng J. The effect of proton pump inhibitor uses on outcomes for cancer patients treated with immune checkpoint inhibitors: a meta-analysis. Ann Transl Med. 2020;8(24):1655. doi:10.21037/atm-20-7498.
   PubMed Web of Science ®Google Scholar
• Imhann F, Bonder MJ, Vich Vila A, Fu J, Mujagic Z, Vork L, Tigchelaar EF, Jankipersadsing SA, Cenit MC, Harmsen HJ, et al. Weersma RK and Zhernakova A. Proton pump inhibitors affect the gut microbiome. Gut. 2016;65(5):740–748. doi:10.1136/gutjnl-2015-310376.
   PubMed Web of Science ®Google Scholar
• Andre T, Amonkar M, Norquist JM, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt CJA, Smith D, Garcia-Carbonero R, et al. Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial. Lancet Oncol. 2021;22(5):665–677. doi:10.1016/S1470-2045(21)00064-4.
   PubMed Web of Science ®Google Scholar
• Kojima T, Shah MA, Muro K, Francois E, Adenis A, Hsu C-H, Doi T, Moriwaki T, Kim S-B, Lee S-H, et al. Randomized Phase III KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer. J Clin Oncol. 2020;38(35):4138–4148. doi:10.1200/JCO.20.01888.
   PubMed Web of Science ®Google Scholar
• Smyth EC, Gambardella V, Cervantes A, Fleitas T. Checkpoint inhibitors for gastroesophageal cancers: dissecting heterogeneity to better understand their role in first-line and adjuvant therapy. Ann Oncol. 2021;32(5):590–599. doi:10.1016/j.annonc.2021.02.004.
   PubMed Web of Science ®Google Scholar
• Brusselaers N, Lagergren J, Engstrand L. Duration of use of proton pump inhibitors and the risk of gastric and oesophageal cancer. Cancer Epidemiol. 2019;62:101585. doi:10.1016/j.canep.2019.101585.
   PubMed Web of Science ®Google Scholar
• Lei WY, Wang JH, Yi CH, Liu TT, Hung JS, Wong MW, Bair MJ, Vaezi MF, Wc O, Cl C. Association between use of proton pump inhibitors and colorectal cancer: a nationwide population-based study. Clin Res Hepatol Gastroenterol. 2021;45:101397. doi:10.1016/j.clinre.2020.02.017.
   PubMed Web of Science ®Google Scholar
• Chaput N, Lepage P, Coutzac C, Soularue E, Le Roux K, Monot C, Boselli L, Routier E, Cassard L, Collins M, et al. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Ann Oncol. 2019;30(12):2012. doi:10.1093/annonc/mdz224.
   PubMed Web of Science ®Google Scholar
• Dubin K, Callahan MK, Ren B, Khanin R, Viale A, Ling L, No D, Gobourne A, Littmann E, Huttenhower C, et al. Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis. Nat Commun. 2016;7(1):10391. doi:10.1038/ncomms10391.
   PubMed Web of Science ®Google Scholar
• Wang F, Yin Q, Chen L, Mm D. Bifidobacterium can mitigate intestinal immunopathology in the context of CTLA-4 blockade. Proc Natl Acad Sci U S A. 2018;115(1):157–161. doi:10.1073/pnas.1712901115.
   PubMed Web of Science ®Google Scholar
• Wang Y, Wiesnoski DH, Helmink BA, Gopalakrishnan V, Choi K, DuPont HL, Jiang ZD, Abu-Sbeih H, Sanchez CA, Chang CC, et al. Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. Nat Med. 2018;24(12):1804–1808. doi:10.1038/s41591-018-0238-9.
   PubMed Web of Science ®Google Scholar
• Luo B, Zhang Y, Zhang C, Liu X, Shi C. Intestinal microbiota: a potential target for enhancing the antitumor efficacy and reducing the toxicity of immune checkpoint inhibitors. Cancer Lett. 2021;509:53–62. doi:10.1016/j.canlet.2021.04.001.
   PubMed Web of Science ®Google Scholar
• Lurienne L, Cervesi J, Duhalde L, De Gunzburg J, Andremont A, Zalcman G, Buffet R, Bandinelli PA. NSCLC immunotherapy efficacy and antibiotic use: a systematic review and meta-analysis. J Thorac Oncol. 2020;15(7):1147–1159. doi:10.1016/j.jtho.2020.03.002.
   PubMed Web of Science ®Google Scholar